Rate My Professor Paul Tooney

Paul Tooney's research career began in cancer biology, pivoted to schizophrenia neurobiology and genetics from 1998 to 2017, where he contributed to the establishment of the Australian Schizophrenia Research Bank, enabling over 100 research projects and publications. Since 2017, he has focused on brain cancers, particularly glioblastoma, exploring new and repurposed drugs to overcome resistance, blood-based biomarkers for diagnosis and treatment monitoring, and the brain tumor microenvironment. His multidisciplinary collaborations include neuroscientists, oncologists, neuropathologists, and chemists. Key publications include 'Patient-derived glioblastoma cells are capable of forming tube-like structures in vitro suggestive of vasculogenic mimicry' (Neuro-Oncology, 2024), 'ATR inhibitors increase the anti-proliferative effects of standard treatment on patient-derived glioblastoma cells' (Neuro-Oncology, 2024), 'Schizophrenia risk from complex variation of complement component 4' (Nature, 2016), and 'Increased white matter neuron density in a rat model of maternal immune activation - Implications for schizophrenia' (Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2016). He mentors postdoctoral scientists and higher degree research students, fostering the next generation of researchers.